source
- China aims for 25% of global first-in-class drugs by 2030 under new five-year planChina's government has set an ambitious target to capture at least a quarter of the world’s first‑in‑class drug discoveries by 2030. The goal is part of a five‑year plan released by the National Me…
- New KRAS-targeting drug daraxonrasib approved for pancreatic cancer as experts call for $100 billion NIH budgetThe FDA has approved daraxonrasib, a therapy from Revolution Medicines that targets the KRAS mutation in pancreatic cancer. The drug is intended for patients who have already received treatment and…